Novel-smoothened inhibitors for therapeutic targeting of naïve and drug-resistant hedgehog pathway-driven cancers

Qingrou Li(Fudan University), Ker Yu(Fudan University)

Acta Pharmacologica Sinica

May 18, 2018

10.1038/s41401-018-0019-5

Cited by 42

Related Papers

mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer.

|Endocrine Related Cancer|2001|418

Discovery of lactoquinomycin and related pyranonaphthoquinones as potent and allosteric inhibitors of AKT/PKB: mechanistic involvement of AKT catalytic activation loop cysteines

|Molecular Cancer Therapeutics|2007|58

mTOR complex-2 stimulates acetyl-CoA and <i>de novo</i> lipogenesis through ATP citrate lyase in HER2/PIK3CA-hyperactive breast cancer

|Oncotarget|2016|47